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ABSTRACT 
The European Federation for Pharmaceutical Sciences (EUFEPS) was founded 25 
years ago by more than 20 national pharmaceutical societies and faculty members. As a pan-
European organisation it brings together pharmaceutical societies as well as academic, 
industrial, and regulatory scientists engaged in drug research and development, drug 
regulation, and education of professionals working in these fields.  
EUFEPS represents pharmaceutical sciences in Europe and is recognised as such 
by both the European Commission and the European Medicines Agency. EUFEPS cooperates 
with the European Federation of Pharmaceutical Industries and other European organisations 
and maintains global connections with agencies such as the US Food and Drug 
Administration and the American Association of Pharmaceutical Scientists.  
EUFEPS has established specified networks forming the basis of its activities. The 
creation of a Network on Veterinary Medicines is prompted by the manifold problems 
resulting from the use of veterinary drugs and its inherent interconnections with human 
medicine, environmental and public health. A long-term goal of this initiative is to expand the 
spectrum of available therapeutics for use in animals, including the development of 
innovative delivery systems.  
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There are currently many national or international organisations and societies 
devoted to promoting veterinary sciences as a whole. These include the World Organization 
for Animal Health (OIE), the Global Animal Medicines Association (Health for Animals), the 
World Veterinary Organisation, the World Small Animal Veterinary Association (WSAVA), 
the World Association for Advancement of Veterinary Parasitology (WAAVP), and the 
European Board of Veterinary Specialisation (EBVS) as well as the European College of 
Veterinary Pharmacology and Toxicology (ECVPT). A key prerogative of these 
organisations is to contribute toward improved animal health and animal welfare in 
conjunction with efforts to address various issues related to animal diseases and public health. 
In this publication, we report on a new Network of the European Federation for 
Pharmaceutical Sciences (EUFEPS) specifically focusing on all scientific aspects of 
veterinary pharmaceuticals related to preclinical research, pharmaceutical quality, clinical 
use, legislation and regulatory policy as well as education and academic training (Dencker et 
al., 2016). 
 
The European Federation for Pharmaceutical Sciences (EUFEPS)  
EUFEPS is a pan-European organisation founded 25 years ago by more than 20 
national pharmaceutical societies and faculty members. It combines pharmaceutical societies 
and scientists engaged in drug research and development, drug regulation, policymaking and 
education of professionals in the field. As an independent organisation, it constitutes a 
platform to enable interdisciplinary collaborations that will lead to safe, effective, innovative, 
economic, and timely medicines (EUFEPS, 2016). 
The European Commission recognises EUFEPS as an integrative body representing 
pharmaceutical sciences within Europe. Additionally, the European Medicines Agency 
(EMA) acknowledges EUFEPS as a neutral scientific resource providing independent 
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opinions on draft regulatory guidelines. EUFEPS works with other European organisations, 
such as the European Federation of Pharmaceutical Industries and Associations (EFPIA), to 
help identifying industrial needs and promoting education in the field of pharmaceutical 
sciences. Other initiatives include the New Safe Medicines Faster-project proposed at the EU 
6th RTD Framework Programme for Research and Technological Development (Bjerrum & 
Linden, 2011). Bringing together European scientists from all disciplines within the 
pharmaceutical sciences is a main goal of EUFEPS. 
EUFEPS plays an active role in all international discussions that relate to 
pharmaceutical sciences across the globe. It is recognised as a key stakeholder by the US 
Food and Drug Administration (FDA), and it works actively with its sister organisation, the 
American Association of Pharmaceutical Scientists (AAPS). Additionally, EUFEPS 
collaborates with the International Pharmaceutical Federation (FIP) and maintains close ties 
with many other international organisations in the field of pharmaceutical sciences (EUFEPS, 
2016).  
 
EUFEPS Networks 
EUFEPS Networks and their steering committees primarily move EUFEPS 
scientific activities forward. Already established EUFEPS Networks include the Networks on 
Safety Sciences, Environment and Pharmaceuticals, NanoMedicine, Regulatory Science, 
PharmacoGenomics Research and Implementation (EPRIN), Bioavailability and 
Biopharmaceutics, and Systems Pharmacology (Table 1).  
 
Approximate Space for Table 1 
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Through the establishment of a new Network on Veterinary Medicines, EUFPS 
expands its array of existing Networks and its relevance in the area of veterinary 
pharmaceutical sciences. All EUFEPS Networks have the potential to be partners for future 
collaboration with the Network on Veterinary Medicines.  
EUFEPS Networks could therefore significantly help solve many problems related 
to the availability and clinical use of therapeutics for farm and pet animals, such as 
antimicrobials and antiparasitic substances, and new drug administration forms, including the 
evaluation of user safety and potential ecologic effects. Moreover, the scientific background 
and experience of EUFEPS could be valuable for the assessment of ongoing regulatory issues 
and legal aspects, graduate and postgraduate education and training (Table 2). 
 
Approximate space for Table 2 
 
Ongoing issues related to veterinary medicines  
In line with the “One Health” principle, a strong connection between human and 
veterinary medicine is essential. The Network on Veterinary Medicines within the EUFEPS 
framework will contribute to this objective in the future. In fact, many of the present or 
emerging problems and prospects of veterinary medicine are best initiated using the 
instruments of multidisciplinary communication and cooperation. Several “One Health”-foci 
are summarised in Tab. 3. Virtually all of these issues overlap with the activities of 
established EUFEPS Networks. 
 
Approximate space for Tab. 3 
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Objects of the Network on Veterinary Medicines in summary 
A long-term goal of the veterinary network is to leverage the various sets of 
expertise offered by the EUFEPS to expand the spectrum of therapeutics intended for use in 
animals, including immunological products, vaccines, novel therapies or innovative drug 
delivery systems.  
The objectives of the veterinary network can be summarised as follows:  
 Strengthening interactions between human, pharmaceutical and veterinary 
sciences, thus fostering interdisciplinary exchanges of expertise between these 
disciplines;  
 Strengthening academic research in related disciplines to promote the 
emergence of new concepts, principles and mechanisms of action to develop 
innovative VMPs;  
 Supporting the development of academic research and collaboration in the 
fields of veterinary and pharmaceutical sciences with particular regard to more 
efficient, safe, and innovative VMPs. All veterinary and pharmacy faculties, as 
well as other related disciplines, are expected to benefit from such network 
activities; 
 Scientifically advancing technologies including in silico/mathematical 
approaches involved in the analysis of metabolomics and proteomics, drug residues 
monitoring and related screening techniques (Mochel et al., 2013); 
 Contributing to the control of regulated therapeutics, including growth-
promoters and substances derived from genetic editing. This is also true for 
international standards, guidelines and rules that apply to sport animals. Achieving 
this goal requires international cooperation with and between the official bodies 
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involved in regulating and controlling the marketing and use of VMPs, as well as 
the involvement of international anti-doping organisations; 
 Encouraging and supporting education, training and continuing professional 
education for future healthcare professionals working in veterinary and 
pharmaceutical practice, academia or industrial research and development. 
 
It is a further goal of this new Network to encourage the European Commission to 
initiate calls for research in the area of veterinary medicines, under, for instance, Horizon 
2020, and forming strong consortia for application to funding opportunities (IMI, EU-
funding).  
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Table 1: Present EUFEPS Networks a. All Networks inherently constitute a positive setting for research, development and evaluation of veterinary 
pharmaceuticals  
 
Network Scope and aim 
Bioavailability and 
Biopharmaceutics 
Biopharmaceutics form the bedrock of many of the activities of the societies contributing to the EUFEPS ("Member 
Societies"). The activities of this network have provided important opportunities to assist the legislature in defining 
a harmonised approach across Europe (e.g., bioavailability and bioequivalence guidelines). Efforts focus on 
scientific questions which arise from poorly understood areas.  
PharmacoGenomics 
Research and 
Implementation 
This Network provides a platform focusing on research and how to best apply findings and learning in practice. 
This includes collaborative contributions to personalised medicines or precision medicine by promoting 
pharmacogenetic/genomic knowledge and expertise in establishing clinical evidence for safe and effective 
medicines and treatments using medication, based on a patient's genetic or other predisposition. 
Environment and 
Pharmaceuticals 
This Network addresses scientific achievements and discusses various issues related to pharmaceutical exposure in 
the environment, including attempts towards global harmonisation. 
NanoMedicine 
This Network focuses on pharmaceutical and biomedical sciences and the diagnostic and therapeutic aspects of 
nanomedicine, primarily in cooperation with related nanotechnology fields. 
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a Their common aims lie in the promotion of scientific collaboration, cooperation and coordination, support of joint activities and engagement in 
education and training. Thus, forums for academic, industrial and regulatory professionals in respective scientific fields have been developed. 
Systems Pharmacology is an emerging new Network, as is the one proposed in this article – Veterinary Medicines (quoted from Dencker et al. 
(2016)). Reprinted from European Journal of Pharmaceutical Sciences 91, L. Dencker, K. Hellmann, J. Mochel, S. Şenel, E. Tyden, J.C. Vendrig, H. 
Linden, I. Schmerold, Position Paper: EUFEPS Network on Veterinary Medicines Initiative: An interdisciplinary forum to support Veterinary 
Pharmacology and promote the development of new pharmaceuticals for Animal Health, I–VII, Copyright (2016), with permission from Elsevier. 
 
Quality by Design (QbD) 
and Process Analytical 
Technology (PAT) Sciences 
This Network powers science-based process understanding and quality-by-design for medicines. It also contributes 
to education and training in the field and fosters hands-on implementation of systems approaches and emerging 
technologies in pharmaceutical production processes.  
Regulatory Science 
This Network offers academic, industrial and regulatory professionals in the various scientific fields brainstorming 
meetings, workshops and discussions on strategic goals and key issues in translational research covered by the 
pharmaceutical sciences.  
Safety Sciences 
This Network is dedicated to the development of safety sciences for medicines. It has organised several workshops 
focusing on education and training for safety scientists. The European Innovative Medicines Initiative (IMI) 
education and training project on safety sciences stems from this Network and is still on-going. 
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Table 2: Conceivable scientific exchange of the Network on Veterinary Medicines with established EUFEPS Networks 
Relevant issues of the Network for Veterinary Medicines Suitable Networks for joint activities 
Strengthening interactions between medical, pharmaceutical and veterinary sciences  Quality by Design (QbD) and Process 
Analytical Technology (PAT) Sciences 
Regulatory Science 
Safety Sciences 
Strengthening academic research (new concepts, principles and mechanisms of action); 
development of innovative new VMPs including innovative delivery systems  
NanoMedicine 
PharmacoGenomics Research and 
Implementation 
Novel individualised medication; legal (and illegal) use of pharmaceuticals (including 
growth-promoting compounds)  
PharmacoGenomics Research and 
Implementation 
Regulatory Science 
Safety Sciences 
Analysis of metabolomics and proteomics, veterinary drug residue monitoring  Safety Sciences  
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Bioavailability and Biopharmaceutics;  
Ecotoxicity of VMPs (fate and biological activity of the VMP ingredients and metabolites 
excreted via urine or faeces in the environment) 
Environment and Pharmaceuticals 
Veterinary drug regulatory processes (assessment, authorisation, supervision of VMPs); 
strategy discussion, science policy  
Regulatory Science 
Education and training of healthcare professionals in veterinary practice, pharmacy, or 
industrial research 
All EUFEPS Networks 
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Table 3: Continuing issues related to Veterinary Medicine 
Thematic area Case example Remarks Problem Reference 
One health 
paradigm 
Common use of 
pharmaceutical substances 
in human and veterinary 
medicine 
All classes of antibacterial substances 
used in veterinary medicine are also 
registered for use in human medicine 
3rd and 4th generation 
cephalosporins, quinolones, 
macrolides and polymyxins have 
been categorized as “Highest 
Priority Critically Important 
Antimicrobials” for Human Use 
by the WHO 
WHO, 2017 
Public health  
 
Environment 
Only food derived from 
healthy animals can ensure 
safe and edible livestock 
products 
Animal diseases are expected to 
reduce global production of food 
animals by more than 20% 
Spread of (zoonotic) bacteria 
conveying antimicrobial 
resistance genes, drug residues 
in animal edible tissues and 
products, or the presence of 
veterinary antibiotics in soil and 
water 
Vallat, 2015; 
EFSA and ECDC, 2017; 
Kümmerer, 2003; 
Xi et al., 2009 
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Development of 
new therapeutic 
strategies 
The global emergence and 
spread of antimicrobial 
resistance are a threat to 
effective prevention and 
treatment of infectious 
diseases 
Sales data from 26 EU/EEA countries 
in 2012 amount to 7982.0 tons of 
antimicrobials used in food-producing 
animals; this is twice the amount of 
antibiotics reported for human 
medicine  
New pharmacological, 
biological or alternative 
approaches are needed to reduce 
the overall use of antibacterials 
in animals 
ECDC/EFSA/EMA, 
2015; 
EMA, 2014; 
EMA, 2016 
 Parasitic helminths become 
increasingly insensitive to a 
wide array of anthelmintic 
drugs 
Since the introduction of ivermectin in 
1981, no novel anthelmintic drug class 
has been developed for use in 
livestock or horses, except for 
monepantel 
 
Widespread antiparasitic 
resistance to benzimidazoles, 
tetrahydropyrimidines, and 
macrocyclic lactones in 
developing countries 
Gill et al., 1998; 
Cezar et al., 2010; 
Kaplan & 
Vidyashankarb, 2012 
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Regulatory issues The complex regulatory 
framework regulating 
Veterinary Medicinal 
Products is presently being 
revised 
The EMA has recently launched an 
initiative to develop a framework for 
stronger collaboration between 
pharmaceutical industry and 
academia 
Several issues related to 
pharmaceutical research and 
development in human and 
veterinary medicine can only be 
solved by interdisciplinary and 
transparent cooperation 
EMA, 2016; 
European 
Commission, 2014 
 
Postgraduate 
training 
Modern teaching 
techniques are invaluable 
tools for the continuous 
education of veterinary 
professionals 
Topics of significance may differ 
from those developed in a more 
standard academic curriculum and 
could include strategies for finding 
and developing promising 
pharmacological candidates for use 
in animals 
Continuous professional 
development should cover technical, 
scientific, regulatory and ethical 
developments and motivate 
professionals to participate in 
lifelong learning relevant to their 
profession 
Directive 2013/55/EU 	
 
 
